Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for ...
Prevalence of major adverse cardiac events in men with prostate cancer receiving androgen deprivation therapy in real-world clinical practice. Early prostate specific antigen response and overall ...
FORT MYERS, Fla., Jan. 22, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 ...
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...
Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...
New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results